TC-G 24CAS# 1257256-44-2 |
2D Structure
- Nadifloxacin
Catalog No.:BCC4804
CAS No.:124858-35-1
- Calcipotriol monohydrate
Catalog No.:BCC1445
CAS No.:147657-22-5
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- Dihydroartemisinin
Catalog No.:BCN6264
CAS No.:71939-50-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1257256-44-2 | SDF | Download SDF |
PubChem ID | 49857866 | Appearance | Powder |
Formula | C15H11ClN4O3 | M.Wt | 330.73 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 10 mM in DMSO with gentle warming | ||
Chemical Name | N-(3-chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine | ||
SMILES | CC1=C(C=C(C=C1)NC2=NN=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])Cl | ||
Standard InChIKey | JYCNWQGNEJYDQS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H11ClN4O3/c1-9-2-5-11(8-13(9)16)17-15-19-18-14(23-15)10-3-6-12(7-4-10)20(21)22/h2-8H,1H3,(H,17,19) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent GSK-3β inhibitor (IC50 = 17 nM); displays selectivity for GSK-3β over CDK2 (22% inhibition at 10 μM). Increases liver glycogen reserves in rodents. Brain penetrant. |
TC-G 24 Dilution Calculator
TC-G 24 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0236 mL | 15.1181 mL | 30.2361 mL | 60.4723 mL | 75.5904 mL |
5 mM | 0.6047 mL | 3.0236 mL | 6.0472 mL | 12.0945 mL | 15.1181 mL |
10 mM | 0.3024 mL | 1.5118 mL | 3.0236 mL | 6.0472 mL | 7.559 mL |
50 mM | 0.0605 mL | 0.3024 mL | 0.6047 mL | 1.2094 mL | 1.5118 mL |
100 mM | 0.0302 mL | 0.1512 mL | 0.3024 mL | 0.6047 mL | 0.7559 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- TC-SP 14
Catalog No.:BCC7926
CAS No.:1257093-40-5
- ABT-199
Catalog No.:BCC3614
CAS No.:1257044-40-8
- TPTU
Catalog No.:BCC2827
CAS No.:125700-71-2
- TDBTU
Catalog No.:BCC2825
CAS No.:125700-69-8
- TBTU
Catalog No.:BCC2823
CAS No.:125700-67-6
- (-)-Epicatechin gallate
Catalog No.:BCN6327
CAS No.:1257-08-5
- Lavendustin A
Catalog No.:BCN1808
CAS No.:125697-92-9
- Lavendustin B
Catalog No.:BCN1809
CAS No.:125697-91-8
- CDK4 inhibitor
Catalog No.:BCC4242
CAS No.:1256963-02-6
- 2''-O-acetyl-platyconic acid A
Catalog No.:BCN3318
CAS No.:1256935-30-4
- 3''-O-acetyl-platyconic acid A
Catalog No.:BCN3319
CAS No.:1256935-28-0
- Blinin
Catalog No.:BCN8455
CAS No.:125675-09-4
- NPEC-caged-noradrenalin
Catalog No.:BCC7835
CAS No.:1257323-83-3
- NPEC-caged-(S)-AMPA
Catalog No.:BCC7789
CAS No.:1257323-84-4
- NPEC-caged-(S)-3,4-DCPG
Catalog No.:BCC7652
CAS No.:1257323-85-5
- NPEC-caged-serotonin
Catalog No.:BCC7836
CAS No.:1257326-22-9
- NPEC-caged-dopamine
Catalog No.:BCC7837
CAS No.:1257326-23-0
- GSK 789472 hydrochloride
Catalog No.:BCC7818
CAS No.:1257326-24-1
- TC-E 5006
Catalog No.:BCC7981
CAS No.:1257395-14-4
- TBA354
Catalog No.:BCC6459
CAS No.:1257426-19-9
- Amikacin hydrate
Catalog No.:BCC4621
CAS No.:1257517-67-1
- CEP-33779
Catalog No.:BCC2199
CAS No.:1257704-57-6
- Pristimerin
Catalog No.:BCN2315
CAS No.:1258-84-0
- Parathyroid Hormone (1-34), bovine
Catalog No.:BCC1040
CAS No.:12583-68-5
Discovery of novel GSK-3beta inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.[Pubmed:21082766]
J Med Chem. 2010 Dec 23;53(24):8534-45.
Dysregulation of glycogen synthase kinase (GSK-3beta) is implicated in the pathophysiology of many diseases, including type-2 diabetes, stroke, Alzheimer's, and others. A multistage virtual screening strategy designed so as to overcome known caveats arising from the considerable flexibility of GSK-3beta yielded, from among compounds in our in-house database and two commercial databases, new GSK-3beta inhibitors with novel scaffold structures. The two most potent and selective validated hits, a 2-anilino-5-phenyl-1,3,4-oxadiazole (24) and a phenylmethylene hydantoin (28), both exhibited nanomolar affinity and selectivity over CDK2 and were potent enough for direct in vivo validation. Both were able to cause significant increases in liver glycogen accumulation in dose-dependent fashion. One also exhibited excellent blood-brain barrier permeability, the other adequate for a lead compound. Analogues of the oxadiazole 24 were synthesized to experimentally corroborate or rule out ligand-bound structures arising from docking studies. SAR results supported one docking study among a number of alternatives.